Ziopharm Oncology reported $-9788000 in Pre-Tax Profit for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Pre Tax Profit Change
Biogen BIIB:US $ 874.8M 28.6M
Curis CRIS:US $ -15.94M 0.17M
Eleven Biotherapeutics EBIO:US $ -0.81M 9.75M
Immunogen IMGN:US $ -62.02M 37.88M
Intercept Pharmaceuticals ICPT:US $ -20.32M 3.04M
Intrexon XON:US $ -19.31M 5.71M
Karyopharm Therapeutics KPTI:US $ -48941000 7.67M
Novartis NOVN:VX SF 4129M 217M
Ptc Therapeutics PTCT:US $ -148.7M 26.8M
Sangamo Biosciences SGMO:US $ -43.09M 0.83M
Tg Therapeutics TGTX:US $ -69.01M 24.32M
Verastem VSTM:US $ -16.96M 0.48M
Ziopharm Oncology ZIOP:US $ -9.79M 2M